Bio-Rad Laboratories, Inc. logo
Bio-Rad Laboratories, Inc. (BIO)
Compare

Bio-Rad Laboratories, Inc. (BIO) Stock Price: $297.17+5.86 (+2.01%)

The total return cagr for Bio-Rad Laboratories, Inc. (BIO) stock is 31.77% over the past 12 months. The 3 year average growth rate is -6.28% and the 5 year cagr is -12.56%. Total return includes dividends reinvested.

The closing share price for Bio-Rad Laboratories, Inc. (BIO) stock was $297.17 for Wednesday, June 3, 2026, up +2.01% from the previous day.

BIO Price Chart

End-of-day pricesAdvanced chart →
BIO$304.83 32.24%as of Jun 3, 2026

BIO Earnings Preview

Next Earnings Date

Jul 30, 2026

51 days away

EPS Estimate

1.75

Revenue Est.

$623.99M

Last Quarter Results

EPS

$1.89

vs Estimate

$1.99

Missed

Revenue

$592.10M

vs Estimate

$589.91M

Met

BIO Analyst Ratings

Consensus Rating

Hold

Based on 5 analysts

Strong Buy
1
Buy
0
Hold
4
Sell
0
Strong Sell
0

Average Price Target

$297.00

-0.1% downside

Low

$275.00

Current

$297.17

High

$320.00

BIO Analyst Estimates

Forward P/E: 29.82

Earnings Per Share (EPS) Estimates

Quarterly

PeriodLowAvgHigh# Analysts
Q1 2027N/A$2.38N/A1
Q2 2027N/A$2.40N/A1
Q3 2027N/A$2.55N/A1
Q4 2027N/A$2.74N/A1

Annual

PeriodLowAvgHigh# Analysts
FY 2027N/A$9.96N/A2
FY 2028N/A$11.15N/A1

Revenue Estimates

Quarterly

PeriodLowAvgHigh# Analysts
Q1 2027N/A$612.50MN/A1
Q2 2027N/A$649.98MN/A1
Q3 2027N/A$677.66MN/A1
Q4 2027N/A$730.47MN/A1

Annual

PeriodLowAvgHigh# Analysts
FY 2027N/A$2.66BN/A2
FY 2028N/A$2.76BN/A1

Source: FMP Analyst Consensus Estimates. Forward P/E calculated using average EPS estimate for the nearest fiscal year.

BIO Competitors' Key Metrics

StockMarket CapClose PricePrice ChangeTTM Total Return5Y CAGR10Y CAGR
1BIO$8.03B$297.17+2.01%+31.77%-12.56%+7.17%

About Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.

Hercules, CA
7,700 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Norman D. Schwartz